This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages without signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Dengue-like fever

Authoring team

  • chikungunya fever is a viral infection caused by an alphavirus (family Togaviridae) found in humans and non-human primates
  • the virus is transmitted primarily by daylight-biting Aedes mosquitoes (for example Aedes aegypti and Aedes albopictus)
  • the name "chikungunya" derives from Swahili, meaning "stooped over," "that which bends up," or "walking bent over," reflecting the prominent symptom of severe joint pain (arthralgia)

Epidemiology and Transmission

  • natural cycles include human-mosquito-human transmission and an African forest epizootic cycle involving monkeys
  • Aedes aegypti (domestic vector) is closely associated with human habitation, feeding almost exclusively on humans throughout the tropics
  • Aedes albopictus (Asian tiger mosquito) feeds on mammals and birds, can thrive away from human habitation, and was implicated in the major Réunion outbreak (265,000 cases; 34% of the population) (1)
  • circulates in tropical and subtropical regions of Asia, Africa, Latin America, and the Caribbean; established vectors in parts of southern Europe present a risk for localized European transmission

Clinical Features

  • incubation period is typically 2 to 7 days
  • acute onset features include high fever, severe joint pain (arthralgia), muscle pain (myalgia), headache, nausea, vomiting, photophobia, and a maculopapular rash
  • joint pain is often debilitating, typically affecting small peripheral joints (wrists, ankles); while usually self-limiting over 1 to 2 weeks, chronic arthralgia can persist for months or years in a significant proportion of patients (4)
  • high-risk groups for severe disease include adults aged over 65 years, neonates, and immunocompromised individuals
  • presentation varies by age: infants often show abrupt fever, facial flushing, and generalized rash 3 to 5 days later; older children present with fever, headache, myalgia, and arthralgia; adults predominantly present with severe arthralgia or arthritis

Diagnosis and Treatment

  • diagnostic confirmation: IgM-capture ELISA or reverse-transcriptase PCR (RT-PCR) on acute-phase samples
  • management is predominantly supportive (analgesia, hydration, and rest); DMARDs (methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine) have been used for persistent post-viral arthralgia but show limited efficacy (5)
  • standard mosquito bite avoidance measures remain essential for prevention

Vaccination Policy and UK Guidance

  • Vimkunya (VLP vaccine): a non-replicating virus-like particle (VLP) vaccine licensed in the UK for individuals aged 12 years and over (8)
  • JCVI advice: may be considered for individuals aged 12 years and over travelling to areas with active outbreaks, long-term or frequent travellers to transmission areas in the past 5 years, or laboratory staff working with the virus (9)
  • immunogenicity: elicits seroresponse rates of 98% (ages 12 to 64 years) and 87% (ages 65 years and over) at 22 days post-vaccination, falling to 86% and 76% respectively at 6 months (9)
  • platform safety: because safety concerns regarding IXCHIQ were specific to its live-attenuated platform, the JCVI does not advise additional restrictions on Vimkunya (9)
  • IXCHIQ (live-attenuated vaccine): live-attenuated chikungunya vaccine (6); following a safety review by the Commission on Human Medicines (CHM) regarding serious adverse events in older adults, the MHRA withdrew its UK marketing authorisation (7, 9)
  • UK guidance: healthcare professionals must not prescribe, supply, or administer IXCHIQ, and must update materials to remove references to it; travellers previously vaccinated with IXCHIQ do not require specific action unless experiencing suspected adverse reactions (7)

Reference:

  1. Anon. Epidémie de chikungunya à La Réunion. Cire La Réunion-Mayotte. 2006.
  2. Ligon BL. Chikungunya: an overview. Semin Pediatr Infect Dis. 2006;17(2):99-104.
  3. Mourya DT, Mishra AC. Chikungunya fever. Lancet. 2006;368(9531):186-187.
  4. Brighton SW et al. Chikungunya virus infection: a retrospective study of 107 cases. S Afr Med J. 1983;63:313-315.
  5. de Lima Cavalcanti TYV et al. A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. Viruses. 2022;14(5):969.
  6. Ng LFP, Rénia L. Live-attenuated chikungunya virus vaccine. Cell. 2024;187(4):813.
  7. Medicines and Healthcare products Regulatory Agency (MHRA). IXCHIQ chikungunya vaccine: UK marketing authorisation withdrawn following safety review. Drug Safety Update. 2026;20(3):2.
  8. Medicines and Healthcare products Regulatory Agency (MHRA). Public Assessment Report: Vimkunya chikungunya vaccine. MHRA. 2025.
  9. Joint Committee on Vaccination and Immunisation (JCVI). Chikungunya vaccine in UK travellers: JCVI advice. GOV.UK. Updated 6 November 2026.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.